Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Traws Pharma (TRAW) Gains from Sales and Divestitures (2022 - 2023)

Traws Pharma (TRAW) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $43567.0 as the latest value for Q3 2023.

For Q3 2023, Gains from Sales and Divestitures rose 43.18% year-over-year to $43567.0; the TTM value through Sep 2023 reached $43567.0, up 43.18%, while the annual FY2022 figure was $30429.0, N/A changed from the prior year.
Gains from Sales and Divestitures hit $43567.0 in Q3 2023 for Traws Pharma, roughly flat from $43567.0 in the prior quarter.
Across five years, Gains from Sales and Divestitures topped out at $43567.0 in Q1 2023 and bottomed at $30429.0 in Q3 2022.